Genentech and OSI Phama Said Avastin/Tarceva Combo Fails As Second-Line Treatment For Lung Cancer
More News related to DNA
- Montura Presents Cost Effective BI Solutions With Relational Object Models
- Bankers Questioning Roche's Ability to Secure $45B Loan to Finance Genentech (DNA) Deal
- IR Global Rankings 2009: Final Registration Deadline Is Today - November 28, 2008
- IR Global Rankings 2009: Registration FINAL Deadline Today
- Genentech (DNA) volatility Elevated at 73
More News related to OSIP
- OSI Pharmaceuticals (OSIP) Said Tarceva Endorsed by the U.K.s National Institute for Health and Clinical Excellence
- Tarceva(R) (erlotinib) Endorsed by the U.K.'s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
- OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 4th
- OSI Pharmaceuticals to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
- Unusual 11 Mid-Day Movers 11/19: LPX, SRS, SKF, OSIP Higher; GNVC, LZB, LNC, GCO Lower
More News related to FDA
- Raymond James Starts Millicom (MICC) at Strong Buy
- Stifel Nicolaus Starts City National (CYN) at Hold
- Stifel Nicolaus Starts eHealth (Nasdaq: HLTH) with a Buy
- Wasserman & Associates initiates coverage on American Physicians Service Group (AMPH) with a Buy
- Jesup & Lamont Initiates Coverage on AutoZone (AZO) with a Hold.
Genentech, Inc. (NYSE: DNA) and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced that a randomized Phase III study (BeTa Lung) evaluating Avastin in combination with Tarceva in patients with advanced non-small cell lung cancer whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo.
The companies said there was clear evidence of clinical activity with improvements in the secondary endpoints of progression-free survival (PFS) and response rate when Avastin was added to Tarceva compared to Tarceva alone in this study.
Link to Release
Related Categories
FDAStocks Mentioned
+3.63
-0.51Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
